Physician profile
Anas Hadeh
NPI 1437360187
$800,084.61
in general payments reported to CMS, 2019-2025
38 companies · $271K in 2025
The $271K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $25K · 2021: $53K · 2022: $92K · 2023: $142K · 2024: $174K · 2025: $271K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $390K · Consulting Fee: $126K · Travel and Lodging: $49K · Food and Beverage: $20K · Honoraria: $2,500 · Education: $27.00 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $389,856.00 |
| Consulting Fee | $125,761.00 |
| Travel and Lodging | $48,753.43 |
| Food and Beverage | $20,290.93 |
| Honoraria | $2,500.00 |
| Education | $27.00 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $399,109.03 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Insmed, INC. | $165,120.13 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $109,653.86 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $62,840.66 | 2021-2025 | |
| Grifols USA, LLC | $25,793.67 | 2022-2025 | Xembify, Albutein |
| Grifols Shared Services North America, INC. | $9,142.22 | 2025 | Xembify |
| Verona Pharma, INC. | $9,065.70 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $4,244.03 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,193.35 | 2019-2025 | Ofev |
| Mannkind Corporation | $3,698.97 | 2025 | |
| Nabriva Therapeutics, Plc | $1,784.02 | 2022 | |
| Merck Sharp & Dohme LLC | $1,501.72 | 2022-2023 | |
| Inari Medical, INC. | $690.00 | 2021-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $509.05 | 2023-2025 | Uptravi, Opsumit |
| Genentech USA, INC. | $406.01 | 2019-2025 | Esbriet, Pulmozyme, Xolair |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $399.91 | 2020-2025 | Tyvaso |
| Baxter Healthcare | $228.13 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $219.68 | 2022-2023 | Yupelri |
| Advanced Respiratory, INC | $207.38 | 2020-2021 | |
| Inspire Medical Systems, INC. | $200.40 | 2025 | Inspire |
| Pulmonx Corporation | $164.13 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Mallinckrodt Enterprises LLC | $145.88 | 2019 | |
| Pharming Healthcare, INC. | $125.00 | 2024 | Ruconest |
| Amgen INC. | $122.66 | 2023 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $108.79 | 2022 | |
| Mallinckrodt Hospital Products INC. | $96.42 | 2020-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $78.86 | 2019 | |
| Philips North America LLC | $47.19 | 2019-2021 | |
| Abbvie INC. | $42.70 | 2021 | |
| Lungpacer Medical USA INC | $30.91 | 2025 | Aeropace Neurostimulation Console |
| Erbe USA INC | $25.00 | 2020-2024 | |
| Becton, Dickinson and Company | $20.06 | 2020 | |
| Gilead Sciences, INC. | $18.51 | 2021 | |
| Ambu INC. | $18.31 | 2021 | |
| Circassia INC. | $17.92 | 2019 | |
| Pinnacle Biologics, INC | $14.35 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Hadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.